Chemclin Diagnostics Co., Ltd. (SHA:688468)

China flag China · Delayed Price · Currency is CNY
7.41
+0.17 (2.35%)
Apr 29, 2026, 3:00 PM CST
5.26%
Market Cap 2.86B
Revenue (ttm) 332.68M
Net Income (ttm) 43.91M
Shares Out 394.59M
EPS (ttm) 0.11
PE Ratio 65.82
Forward PE n/a
Dividend 0.13 (1.71%)
Ex-Dividend Date Jun 13, 2025
Volume 5,404,820
Average Volume 2,907,887
Open 7.20
Previous Close 7.24
Day's Range 7.18 - 7.49
52-Week Range 6.76 - 9.12
Beta 0.13
RSI 46.99
Earnings Date Apr 29, 2026

About Chemclin Diagnostics

Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such as hepatitis B, hepatitis C, AIDS, syphilis, hepatitis A, hepatitis E, etc.; and detection of tumor markers, thyroid hormones, reproductive endocrine ho... [Read more]

Sector Healthcare
Founded 2007
Employees 606
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688468
Full Company Profile

Financial Performance

In 2025, Chemclin Diagnostics's revenue was 332.68 million, a decrease of -23.75% compared to the previous year's 436.29 million. Earnings were 43.91 million, a decrease of -65.44%.

Financial Statements

News

There is no news available yet.